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A BS TR AC T
BACKGROUND
Congenital disorders of glycosylation are genetic syndromes that result in impaired 
glycoprotein production. We evaluated patients who had a novel recessive disorder 
of glycosylation, with a range of clinical manifestations that included hepatopathy, 
bifid uvula, malignant hyperthermia, hypogonadotropic hypogonadism, growth 
retardation, hypoglycemia, myopathy, dilated cardiomyopathy, and cardiac arrest.
METHODS
Homozygosity mapping followed by whole-exome sequencing was used to identify 
a mutation in the gene for phosphoglucomutase 1 (PGM1) in two siblings. Sequencing 
identified additional mutations in 15 other families. Phosphoglucomutase 1 en-
zyme activity was assayed on cell extracts. Analyses of glycosylation efficiency and 
quantitative studies of sugar metabolites were performed. Galactose supplementa-
tion in fibroblast cultures and dietary supplementation in the patients were studied 
to determine the effect on glycosylation.
RESULTS
Phosphoglucomutase 1 enzyme activity was markedly diminished in all patients. 
Mass spectrometry of transferrin showed a loss of complete N-glycans and the 
presence of truncated glycans lacking galactose. Fibroblasts supplemented with 
galactose showed restoration of protein glycosylation and no evidence of glycogen 
accumulation. Dietary supplementation with galactose in six patients resulted in 
changes suggestive of clinical improvement. A new screening test showed good 
discrimination between patients and controls.
CONCLUSIONS
Phosphoglucomutase 1 deficiency, previously identified as a glycogenosis, is also a 
congenital disorder of glycosylation. Supplementation with galactose leads to bio-
chemical improvement in indexes of glycosylation in cells and patients, and supple-
mentation with complex carbohydrates stabilizes blood glucose. A new screening 
test has been developed but has not yet been validated. (Funded by the Netherlands 
Organization for Scientific Research and others.)
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Protein N-glycosylation is a ubiqui-tous process in all organ systems. During N-glycosylation, glycan precursors are as-
sembled from monosaccharide units and then 
covalently attached to asparagine residues in the 
nascent peptide chain of a protein (Fig. 1). The 
protein-bound glycans undergo further process-
ing to generate mature glycoproteins. Genetic 
defects in protein N-glycosylation, designated as 
congenital disorders of glycosylation, lead to 
multisystem disorders. Mutations of genes in-
volved in N-glycosylation may affect either the 
biosynthesis of the glycan precursor (congenital 
disorder of glycosylation type I [CDG-I]) or the 
processing of the glycan after its attachment to 
the protein (congenital disorder of glycosylation 
type II [CDG-II]) (Fig. 1).
Glucose-1-phosphate is an important inter-
mediate in the pathways leading to protein N-
glycosylation and in glucose homeostasis. Phos-
phoglucomutase 1 catalyzes the interconversion 
of glucose-6-phosphate and glucose-1-phosphate 
(Fig. 2).1 In the present study, we evaluated pa-
tients with phosphoglucomutase 1 deficiency, 
which has been identified previously as glyco-
genosis type XIV (Online Mendelian Inheritance 
in Man database number, 612934),2 and with 
glycosylation abnormalities affecting both the 
attachment and the processing of N-glycans.
ME THODS
PATIENTS
We initially identified a pair of male siblings (Pa-
tients 1.1 and 1.2) from a consanguineous family 
(the index family; parents were first cousins) 
with clinical features suggestive of congenital 
disorders of glycosylation, including myopathy, 
hepatopathy, short stature, and hypoglycemia. 
Analysis of serum transferrin by means of iso-
electric focusing was performed to screen for 
congenital disorders of glycosylation.3,4 This 
evaluation revealed an atypical pattern (Fig. 1), 
suggesting a novel disorder.
Several additional affected persons were iden-
tified subsequently. A total of 19 patients from 
16 families (including three sibling pairs) were 
included in the present study, showing clinical 
features suggestive of congenital disorders of 
glycosylation and an atypical pattern on isoelec-
tric focusing (Fig. S1 and Table S1 in the Sup-
plementary Appendix, available with the full 
text of this article at NEJM.org; some features of 
Patients 2, 4, 5.1, 5.2, 6, 8, and 9 have been de-
scribed previously2,5-8). Approval by a human 
subjects committee was obtained for all the 
clinical studies. Written informed consent was 
obtained from all the participants or, in the case 
of children, from a parent or legal guardian.
GENETIC STUDIES
Because the parents of the index family were first 
cousins and were unaffected, we assumed auto-
somal recessive inheritance of the disease. We 
therefore performed homozygosity mapping with 
DNA from the two affected siblings, using Hu-
man1M-Duo BeadChips (Illumina; see the Sup-
plementary Appendix). Within the regions of ho-
mozygosity thus identified, we used whole-exome 
sequencing to identify sequence variants that 
might be associated with the disease. After iden-
tification of mutations in the gene for phospho-
glucomutase 1 (PGM1) in both siblings (see the 
Supplementary Appendix), PGM1 in additional pa-
tients was analyzed by means of Sanger sequenc-
ing (see the Supplementary Appendix).
TISSUE SPECIMENS
Blood samples and skin-biopsy and muscle-biop-
sy specimens were obtained from study partici-
pants after informed consent had been provided. 
Leukocytes were obtained from blood samples. 
Fibroblast cultures were prepared from skin-biopsy 
specimens from 15 patients (see the Supplemen-
tary Appendix). Biopsy specimens of the vastus 
lateralis muscle were obtained from 4 patients. 
Fibroblasts pelleted from cultures, leukocytes, 
and muscle-biopsy specimens were frozen in liq-
uid nitrogen for use in study assays.
PHOSPHOGLUCOMUTASE 1 EXPRESSION  
AND ACTIVITY
Total RNA was extracted from fibroblast pellets, 
and PGM1 messenger RNA (mRNA) was quanti-
fied by means of a real-time polymerase chain 
reaction assay (see the Supplementary Appendix). 
Western blot analysis was performed on cyto-
solic proteins extracted from fibroblast pellets 
with the use of a monoclonal anti-PGM1 anti-
body (see the Supplementary Appendix). Phos-
phoglucomutase 1 enzyme activity was assayed 
spectrophotometrically on extracts from fibro-
blasts, leukocytes, or skeletal-muscle cells (see 
the Supplementary Appendix).
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GLYCOSYLATION ASSAYS
Analysis of transferrin glycosylation was performed 
on serum samples with the use of isoelectric fo-
cusing,3,4 sodium dodecyl sulfate–polyacrylamide-
gel electrophoresis (SDS-PAGE),3 or liquid chro-
matography–mass spectrometry9 (Fig. 3, and 
the Supplementary Appendix). The cell-surface 
glycoprotein intercellular adhesion molecule 1 
(ICAM-1), the expression of which is markedly 
reduced by deficient glycosylation,10 was assayed 
Patient 1.1 has features of 
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Figure 1. Glycoprotein Biosynthesis and Congenital Disorders of Glycosylation.
For the N-glycosylation of proteins, a glycan precursor is assembled from monosaccharide units on an anchoring 
isoprenoid alcohol, dolichol, in the membrane of the endoplasmic reticulum. Each glycan precursor is then trans-
ferred en bloc to a specific asparagine residue in the nascent peptide chain of a protein being synthesized by a ribo-
some and entering the endoplasmic reticulum. Because transferrin (brown line) is abundant in blood, it is used 
as an indicator of the efficiency of the glycosylation system. Transferrin has two glycosylation sites. The protein is 
transported to the Golgi apparatus, and the glycans are modified in multiple steps. Each fully modified glycan is 
terminated with two negatively charged sialic acid residues. Thus, the transferrin molecule carries a total of four 
sialic acid residues. If a genetic defect impairs synthesis of the precursor glycan in the endoplasmic reticulum, 
one or both glycosylation sites of transferrin may remain unoccupied (white arrow). Such defects are classified as 
congenital disorders of glycosylation type I (CDG-I). In congenital disorders of glycosylation type II (CDG-II), the 
defect occurs in the modification of the already-transferred glycan. Both glycosylation residues may carry a glycan, 
but those glycans may be missing terminal sialic acid residues and end with galactose, mannose, or N-acetylglu-
cosamine. Isoelectric focusing (IEF), which separates molecules according to differences in their isoelectric point, 
is used for investigating congenital disorders of glycosylation with the use of an agarose-gel–based system, followed 
by immunoprecipitation in gel with an antibody to transferrin and final staining of the precipitate with Coomassie 
blue. Under conditions of normal glycosylation, most transferrin molecules carry four sialic acid residues (tetrasialo-
transferrin) and form a single major band on IEF. A few transferrin molecules carry five or six sialic acid residues 
that appear as minor bands on IEF (gray numbers; not shown in the molecular-structure diagrams). CDG-I defects 
are easily identified owing to the occurrence of transferrin isoforms with two or no sialic acid residues detected by 
means of IEF. No signal for monosialotransferrin (transferrin with one sialic acid residue) is seen in such disorders. 
In CDG-II, the defect can result in transferrin molecules with no, one, two, three, or four sialic acid residues. A pa-
tient with a CDG-II defect typically has bands of approximately equal intensity at all positions from 0 through 3 or 
a smooth gradient of intensities, whereas in most cases, tetrasialotransferrin shows a more intense signal owing 
to residual activity. In our patients, the signal of transferrin with two sialic acid residues (disialotransferrin) may 
be more intense than those for either one or three residues (as in the sample from Patient 1.1). The signal with 
two sialic acid residues presumably arises from a mixture of transferrin molecules that have one unoccupied gly-
cosylation site as well as transferrin molecules that are occupied at both sites by glycans but have only two ter-
minal sialic acid residues. The patients in this study had features of both CDG-I and CDG-II, as shown by IEF, 
suggesting a novel disorder.
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in fibroblast cultures from patients by means of 
Western blotting and immunofluorescence analy-
sis with the use of a monoclonal anti–ICAM-1 
antibody (see the Supplementary Appendix). Green 
fluorescent protein engineered for retention in the 
endoplasmic reticulum was modified to contain 
an N-glycosylation site that, when glycosylated, 
causes loss of f luorescence (Glyc-ER-GFP).11
Glyc-ER-GFP was transfected into patient fibro-
blasts in culture, and fluorescence was mea-
sured by means of quantitative microscopy (see 
the Supplementary Appendix).
SUGAR METABOLITE AND GLYCOGEN QUANTIFICATION
The nucleotide sugars uridine diphosphate 
(UDP)–glucose and UDP-galactose were extract-
ed from cultured fibroblasts and erythrocytes 
from patients and were quantified by means of 
reverse-phase high-performance liquid chroma-
tography (see the Supplementary Appendix).12,13
Glucose-1-phosphate was analyzed by means of a 
photometric method (see the Supplementary Ap-
pendix), and galactose-1-phosphate was assayed 
with the use of 14C-labeled UPD-glucose.14 Gly-
cogen was extracted from fibroblasts and digested 
with amyloglucosidase as described previously.15
The total amount of glucose was analyzed by means 
of gas chromatography–mass spectrometry.16 Gly-
cogen content in fibroblasts from patients was also 
assessed by means of electron microscopy (see 
the Supplementary Appendix).
GALACTOSE SUPPLEMENTATION IN CULTURE
Galactose (Sigma-Aldrich) was added to fibroblast 
culture medium to increase the concentration of 
intracellular UDP-galactose by means of the galac-
tose-1-phosphate uridyltransferase (GALT) reac-
tion (Fig. 2). The concentration used was 0.5 mM.
DIETARY SUPPLEMENTATION
Galactose powder was supplied by Falcento. Ga-
lactose levels in whole blood were determined in 
a healthy volunteer after the oral consumption of 
250 ml of water in which 0.3 g of galactose per 
kilogram of body weight had been dissolved. 
Measurements of galactose levels in blood were 
made by means of spectrophotometry at intervals 
of 10 minutes during the first hour and at inter-
vals of 30 minutes for an additional 3 hours. Lac-
tose or galactose supplementation was adminis-
tered as an aqueous solution at a dose of 0.5 to 
1.0 g per kilogram per day, divided into three to 
six daily doses (on the basis of patient preference).
SCREENING ASSAY
To develop a potential presymptomatic screening 
test for phosphoglucomutase 1 deficiency, we 
developed a modified version of the Beutler test, 
which is used with Guthrie heel-prick test cards 
(dried blood spots) to screen for galactosemia. 
The Beutler test is dependent on the generation 
of glucose-1-phosphate and its metabolites by 
means of the GALT reaction (Fig. S2 in the Sup-
plementary Appendix). We substituted glucose-
1-phosphate for the substrate in the assay. We 
also developed a similar assay using glucose-
6-phosphate, which we anticipated would bypass 
the enzyme defect in phosphoglucomutase 1 
deficiency.
Glycosylation
Galactose
GALE
GALT
UDP
Glucose
Lactate
Complex
carbohydrates
UDP
Glycogen synthase
Glycogen
phosphorylase
Glycogen metabolism
PGM1
Glycogen
UDP
UGP
1-Phosphate1-Phosphate
6-Phosphate
Phosphate
Energy, fatty acids
Various 
reactions
Figure 2. Role of Phosphoglucomutase 1 in Sugar Metabolism.
When blood glucose is low, glycogen degradation (yellow box) generates 
glucose-1-phosphate, which is converted by phosphoglucomutase 1 (PGM1) 
to glucose-6-phosphate for glucose release from the liver or subsequent 
catabolism in other tissues. In the reverse reaction, glucose-6-phosphate 
is converted to glucose-1-phosphate by means of PGM1 and is used as a 
substrate in the production of uridine diphosphate (UDP)–glucose, which 
can be used for the synthesis of glycogen or for protein glycosylation. Dietary 
galactose may be converted to UDP-galactose by galactose-1-phosphate uridyl-
transferase (GALT) and used for protein glycosylation. UDP-galactose may 
also be converted into UDP-glucose by UDP-galactose epimerase (GALE). 
The GALT reaction is reversible; for clarity, only one direction of the coupled 
GALT reactions is shown. UGP denotes UDP-glucose pyrophosphorylase.
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R ESULT S
CLINICAL PHENOTYPE
A total of 19 affected family members, 3 to 43 
years of age, were identified in 16 families (Table 
S1 in the Supplementary Appendix). At birth, a 
bifid uvula with or without cleft palate was the 
only clinical manifestation.
Subsequent clinical manifestations varied 
among the patients (Fig. 4). Signs of hepatopa-
thy with moderately elevated serum aminotrans-
ferase levels developed in all patients. Dilated 
cardiomyopathy, cardiac arrest, or both occurred 
in six patients; three patients were listed for heart 
transplantation. The majority of the patients had 
muscle symptoms, including exercise intolerance, 
muscle weakness, and rhabdomyolysis. Malig-
nant hyperthermia with severe rhabdomyolysis 
occurred in two patients after the administra-
tion of general anesthesia. Growth retardation 
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Figure 3. Effects of Dietary Galactose on Protein Glycosylation.
The results of mass spectrometry of the intact transferrin protein and corresponding transferrin IEF profiles are 
shown before (Panel A) and after (Panel B) the intake of supplementary galactose. The glycan structures are shown 
in detail with the transferrin protein backbone (brown line). Patients with PGM1 deficiency have highly specific 
transferrin glycosylation profiles. Data from Patient 2 show several peaks indicating the presence of glycoforms 
completely lacking one or both N-glycans (white arrows), a finding that is also observed in CDG-I. There are also 
peaks indicating the presence of glycoforms with truncated glycans lacking galactose (ending with N-acetylglucos-
amine; yellow arrows). Several structures end this way, which is typically seen in CDG-II. Numbers at main peaks 
are deconvoluted mass (amu). Numbers next to the IEF results indicate individual bands corresponding to numbers 
of sialic acid residues (black numbers indicate structures shown along the respective mass spectrum, and gray 
numbers structures not shown). After the patient increased dietary intake of galactose, protein glycosylation was 
substantially improved (Panel B). Peaks indicating the presence of glycoforms with truncated glycans lacking galac-
tose almost completely disappeared, and peaks indicating the presence of glycoforms with complete loss of one or 
both N-glycans were considerably reduced. For details on the method and quantification of isoforms by means of 
liquid chromatography–mass spectrometry, see the Supplementary Appendix.
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was reported in all but four patients. Two girls 
had hypogonadotropic hypogonadism with de-
layed puberty. Hypoglycemia was common, es-
pecially in childhood, requiring treatment with 
frequent meals, complex carbohydrates, or over-
night tube feeding.
TRANSFERRIN GLYCOSYLATION
Transferrin analysis by means of isoelectric fo-
cusing, supplemented by SDS-PAGE data, revealed 
that the affected family members in the other 
families had a distinctive pattern of glycosylation, 
as did the two siblings in the index family (Fig. S1 
in the Supplementary Appendix). Mass spec-
trometry revealed the presence of a variety of 
transferrin glycoforms, including forms lacking 
one or both glycans as well as forms with trun-
cated glycans (Fig. 3A). There was considerable 
variation in the transferrin-glycoform profile 
among the patients (Fig. S4 in the Supplementary 
Appendix).
GENETIC IDENTIFICATION OF 
PHOSPHOGLUCOMUTASE 1 DEFICIENCY
Homozygosity mapping of the two affected sib-
lings in the index family identified autosomal 
regions of homozygosity totaling 87.5 mega-
bases (Fig. S5 in the Supplementary Appendix). 
Whole-exome sequencing identified 1516 sequence 
variants within the regions of homozygosity. 
These variants were filtered to identify 10 genes 
carrying homozygous nonsynonymous muta-
tions that had not already been identified as 
polymorphisms. Two of these genes were con-
sidered to be of potential functional relevance, 
but only the mutation in PGM1 cosegregated 
with disease. Independently, functional filter-
ing of whole-exome sequencing data for poten-
tial CDG-I candidate genes in another patient 
(Patient 6 in Table S1 in the Supplementary Ap-
pendix) led to the identification of a homozy-
gous PGM1 mutation.
A total of 21 different PGM1 mutations were 
identified in 16 families. Nine patients were 
compound heterozygotes; all others were homo-
zygotes. The locations of the individual muta-
tions with respect to the structural domains of 
the phosphoglucomutase 1 protein are shown in 
Fig. S6 in the Supplementary Appendix.
PHOSPHOGLUCOMUTASE 1 EXPRESSION  
AND ACTIVITY
Quantification of PGM1 mRNA was performed 
for 11 patients and showed considerable variation 
in expression (Fig. S7 in the Supplementary Ap-
pendix). Only two homozygous premature stop 
variants with predicted nonsense-mediated decay 
showed mRNA levels that were less than 10% of 
those in healthy controls. Likewise, Western blot-
ting of phosphoglucomutase 1, performed for 13 
patients, showed various amounts of protein 
(Fig. S8 in the Supplementary Appendix). Assays 
for phosphoglucomutase 1 enzyme activity, how-
ever, showed markedly decreased activity in all 
17 patients who were tested, amounting to at 
most 12% of the activity seen in controls (Table 
S1 in the Supplementary Appendix).
0 20 40 60 80 100
Patients with Symptom or Finding (%)
B Symptoms in Patients
A Bifid Uvula
Hepatopathy
Bifid Uvula
Growth
Retardation
Myopathy
Hypoglycemia
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Cardiomyopathy
Figure 4. Overview of Clinical Features of PGM1 Deficiency.
Most patients had a bifid uvula (Panel A). Symptoms or findings related to 
PGM1 deficiency are listed according to frequency (Panel B). Hepatopathy 
was defined as elevated aminotransferase levels, steatosis, fibrosis, or a 
combination of these features. Myopathy was defined as a maximal creatine 
kinase level of more than 300 U per liter. Growth retardation was defined as 
a height at or below the 5th percentile. Hypoglycemia was defined as a 
fasting glucose level of less than 2.2 mmol per liter (40 mg per deciliter).
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SUGAR-METABOLITE AND GLYCOGEN QUANTIFICATION
Analyses of sugar metabolites in fibroblasts from 
patients revealed increased concentrations of 
galactose-1-phosphate and glucose-1 phosphate, 
as compared with fibroblasts from controls. The 
ratio of UDP-galactose to UDP-glucose was de-
creased, suggesting that UDP-galactose is limiting 
for N-glycan biosynthesis (see the Supplementary 
Appendix). Glycogen content, as assessed by means 
of either electron microscopy or gas chromatog-
raphy–mass spectrometry after amyloglucosidase 
digestion, was similar to that seen in fibroblasts 
from controls (see the Supplementary Appendix).
EFFECT OF GALACTOSE SUPPLEMENTATION  
IN CULTURE
With the addition of galactose to the culture me-
dium of fibroblasts from patients, glycosylation 
was substantially enhanced, as assessed by means 
of glycosylation of ICAM-1 (Fig. S9 in the Supple-
mentary Appendix) and Glyc-ER-GFP (Fig. S10 in 
the Supplementary Appendix). The effect on 
Glyc-ER-GFP was further enhanced by the addition 
of uridine to the culture medium, which resulted 
in essentially normal glycosylation of this test 
protein (Fig. S10 in the Supplementary Appendix). 
Glycogen content was not affected by either ga-
lactose or glucose supplementation (Table S3 in 
the Supplementary Appendix).
DIETARY SUPPLEMENTATION
Oral consumption of galactose by a healthy vol-
unteer confirmed the bioavailability of this sugar. 
The plasma concentration of galactose reached a 
maximum of 0.7 mM at 50 minutes and decreased 
to baseline levels after 2 hours (data not shown).
Six study participants (Patients 1.1, 1.2, 2, 
5.2, 6, and 11 in Table S1 in the Supplementary 
Appendix) received dietary supplementation with 
lactose or galactose. Within 2 weeks, transferrin 
glycosylation had improved substantially as shown 
by mass spectrometry (Fig. 3B, and Fig. S11 in the 
Supplementary Appendix). In addition, there was 
substantial improvement in glycosylation of the 
total serum N-glycome (the set of all N-glyco-
sylated proteins) with galactose supplementation 
(Fig. S12 in the Supplementary Appendix).
In Patients 2 and 6, no further episodes of 
rhabdomyolysis occurred after the initiation of 
galactose treatment, and cardiac function re-
mained stable. In these same girls, who were 15 
and 17 years of age, respectively, hypogonado-
tropic hypogonadism resolved within a few 
weeks after the initiation of galactose supple-
mentation. Levels of luteinizing hormone, which 
were initially at the 2.5th percentile, increased in 
these two patients by a factor of 5 and a factor of 
10, respectively; in addition, levels of follicle-
stimulating hormone (FSH) normalized, and 
clinical signs of puberty appeared. Ultrasonogra-
phy of the liver, which was performed every 3 
months in Patients 2 and 6 during galactose 
supplementation, showed no increase in echo-
genicity and no signs of cholestasis.
SELECTIVE SCREENING
We used the standard Beutler test for galactose-
mia as well as two modified versions to deter-
mine whether such a test could reliably identify 
patients with phosphoglucomutase 1 deficiency 
(Fig. S2 in the Supplementary Appendix). In the 
standard Beutler test, the activity of the GALT 
pathway was significantly lower in eight study 
patients with phosphoglucomutase 1 deficiency 
than in healthy newborn controls (Fig. S13 and 
Table S4 in the Supplementary Appendix). The ad-
dition of phosphoglucomutase 1 from rabbit heart 
restored the activity of the GALT pathway in the 
patients to normal levels.
In a modified Beutler test with the use of 
glucose-6-phosphate, which is dependent on the 
activity of glucose-6-phosphate dehydrogenase, 
there was no significant difference between study 
patients and controls. However, in a modified 
Beutler test with the use of glucose-1-phosphate, 
which is dependent on the activity of phospho-
glucomutase 1, there was a significant reduction 
in enzyme activity, as assessed by means of 
NADPH fluorescence, in the patients (Fig. S13 
and Table S4 in the Supplementary Appendix).
DISCUSSION
In our study, we found that phosphoglucomu-
tase 1 deficiency, which has been shown to be a 
glycogen storage disorder, is also a mixed-type 
congenital disorder of glycosylation. We identi-
fied 21 different mutations in PGM1 in 19 pa-
tients. Although all the patients had multisystem 
disease at the time of the study, the only apparent 
clinical feature at birth was a bifid uvula (in 16 of 
the 19 patients).
Extensive use of common protein polymor-
phisms of phosphoglucomutase 1 in paternity 
testing led to the discovery of a case of reduced 
enzyme activity in 1963, and since then additional 
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cases of reduced phosphoglucomutase 1 activity 
have been described sporadically.8,17-22 In 2009, 
data on an adult with exercise-induced muscle 
cramps and episodes of rhabdomyolysis (Patient 
8 in the current study) were reported.2 Abnormal 
glycogen accumulation was noted in the mus-
cles, the level of phosphoglucomutase 1 activity 
was only 1% of the normal level, and mutations 
in PGM1 were identified. The disease was desig-
nated as glycogenosis type XIV. However, the 
broad clinical and biochemical spectrum of phos-
phoglucomutase 1 deficiency remained unrecog-
nized.
In contrast to many other congenital disor-
ders of glycosylation, in which patients have 
psychomotor retardation, the brains of our pa-
tients were not affected. This is probably ex-
plained by the fact that other isoenzymes substi-
tute for phosphoglucomutase 1 in the brain (see 
the Supplementary Appendix).
We did not attempt to show experimentally 
the mechanisms that account for the clinical 
phenotypes of phosphoglucomutase 1 deficiency. 
However, analysis of the literature provides at 
least three different mechanisms. Hypoglycemia, 
lactic acidosis, and exercise intolerance are pre-
sumably consequences of disordered glucose 
metabolism. After a dietary glucose load, large 
amounts of glucose-6-phosphate are generated, 
which cannot be converted into glycogen. Thus, 
a substantial portion is diverted to lactate and 
fatty acid production (Fig. 2). During fasting, liver 
glycogen cannot be converted into glucose via 
glucose-6-phosphate, and hypoglycemia may oc-
cur. The inability of skeletal muscles to quickly 
use glycogen for the anaerobic production of 
energy leads to exercise intolerance and poten-
tially to rhabdomyolysis. These characteristics 
are also seen with glycogen storage disease Ia, 
in which there is a defect in hepatic glucose-
6-phosphatase. Stabilizing glucose homeostasis 
by means of dietary intake of complex carbohy-
drates23 and restricting exercise to a level below 
the aerobic threshold might be beneficial.
Two endocrinologic features of phosphoglu-
comutase 1 deficiency may be directly linked to 
defective glycosylation. First, Patients 2 and 6 had 
hypogonadotropic hypogonadism without clini-
cal manifestations of puberty. The gonadotropins 
and their receptors are glycoproteins, and their 
function has been shown to be reduced by inad-
equate glycosylation.24 Second, 15 patients had 
short stature, although the growth hormone (so-
matotropin) level was normal to high in the pa-
tients in whom it was measured. However, levels 
of insulin-like growth factor 1 (IGF-1) and IGF-
binding protein 3 were low, as they are in pa-
tients with CDG-Ib, a glycosylation disorder in 
which dietary supplementation with mannose im-
proves glycosylation and growth.3,25 A detailed 
discussion of the literature concerning the role 
of glycosylation in the gonadotropin and IGF-1 
systems is provided in the Supplementary Ap-
pendix.
A third mechanism relates PGM1 mutations to 
dilated cardiomyopathy. Phosphoglucomutase 1 
binds to the heart-muscle-cell–specific splice 
variant of ZASP (Z-band alternatively spliced 
PDZ-motif protein), and ZASP mutations that af-
fect the binding of phosphoglucomutase 1 are 
associated with dilated cardiomyopathy.26,27 Our 
study shows that defects in PGM1 are also asso-
ciated with dilated cardiomyopathy. A detailed 
discussion of this mechanism is provided in the 
Supplementary Appendix.
We also found that galactose supplementa-
tion can improve glycosylation both in fibroblast-
cell culture and in patients. The extent to which 
this improvement in glycosylation mitigates the 
clinical features of phosphoglucomutase 1 defi-
ciency was not investigated systematically in our 
study. In the six patients in this study who re-
ceived dietary supplementation with galactose, 
some potentially important clinical changes were 
seen. In the two girls with hypogonadotropic hy-
pogonadism, the levels of luteinizing hormone 
increased markedly, FSH levels normalized, and 
clinical signs of puberty appeared. However, a 
systematic clinical study of the effects of galac-
tose supplementation will be necessary to deter-
mine the extent to which such therapy can cor-
rect the clinical features of this condition; such 
studies will also incidentally help to define the 
pathogenesis of the individual elements of the 
clinical syndrome of phosphoglucomutase 1 de-
ficiency.
We devised a clinical test for the diagnosis of 
phosphoglucomutase 1 deficiency, which was 
based on the Beutler test for galactosemia. On 
initial evaluation, this modified Beutler test ap-
peared to discriminate effectively between persons 
with phosphoglucomutase 1 deficiency and con-
trols. However, validation is required before the 
assay can be recommended for routine clinical use.
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In conclusion, we found that phosphogluco-
mutase 1 deficiency, previously identified as a gly-
cogen storage disorder, is also a mixed-type con-
genital disorder of protein N-glycosylation. The 
presence of a bifid uvula at birth may be an early 
clinical clue to the presence of this syndrome. 
Supplementation with galactose leads to biochem-
ical improvement in indexes of glycosylation. The 
degree to which galactose supplementation may 
lead to clinical improvement in the disease syn-
drome is not yet established.
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